article thumbnail

Latest CMS Data Reveal the Truth About U.S. Drug Spending

Drug Channels

As you will see, retail and mail prescription drug spending remain a consistently small share of the $4.5 And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drug prices. Will drug pricing flat earthers (#DPFE) ever acknowledge the data? (Links below.) healthcare.

article thumbnail

The Drug Discount Ecosystem Needs Clarity in 2024 and Beyond

Drug Channels

Gavin discusses the problems manufacturers face in accessing and standardizing drug discount data. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. These data are necessary to avoid duplicate discounts and comply with regulatory requirements. Read on for Gavin’s insights.

Drugs 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

At the Breaking Point: The Unsustainable Future of Government Drug Discount Programs

Drug Channels

Gavin discusses the three key reasons for duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. He then explains Oregon’s novel approach to fixing the problem. All rights reserved.

article thumbnail

Drug Channels News Roundup, February 2024: Pharmacy Shakeout Update, High Drug Prices, 340B Realities, MDs vs. Pharmacists, and Foo Fighters

Drug Channels

In this issue: An update on the retail pharmacy shakeout Arguing for high drug prices A leading researcher provides a 340B reality check Physicians don’t want pharmacists getting uppity Plus, Dave Grohl fights for your right to…have healthcare price transparency? (I Sorry, no Threads.) All rights reserved.

article thumbnail

How the Biosimilar Boom Boosts Drug Wholesalers’ Profits

Drug Channels

The biosimilar boom for provider-administered drugs continues to accelerate. Below, we share our estimates for wholesalers’ gross margins for brand-name, generic, and biosimilar drugs. We then explain the channel dynamics behind biosimilar and generic drugs’ profits. drug distribution. d/b/a Drug Channels Institute.

article thumbnail

The Drug Discount Ecosystem’s “Mission Critical”

Drug Channels

Vishali discusses the persistent challenges of duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program. To learn more, sign up now for priority access to Kalderos’ 2023 annual report: Mission Critical: Bringing Drug Discount Stakeholders Together so Patients Win.

Drugs 97
article thumbnail

Drug Channels News Roundup, June 2023: Humira Price War and Mark Cuban, Formulary Exclusions, Oncology Drug Benefits, and Our Wonderful Healthcare System

Drug Channels

Before you launch your July 4 festivities, Drug Channels offers some fireworks of our own: My $0.02 on the Humira price war—and the role of cost-plus pharmacy pricing Fresh evidence that formulary exclusions hurt patients Disturbing oncology drug benefit management Plus, an entertaining explanation of why the U.S.